Date | Free Cash Flow | Operating Cash Flow | Net Cash Used For Investing Activities | Net Cash Used Provided By Financing Activities |
---|
CEO | Mr. Xiangting Cai |
IPO Date | Aug. 20, 2020 |
Location | China |
Headquarters | Building 7 |
Employees | 907 |
Sector | Health Care |
Industries |
Guangzhou LBP Medicine Science & Technology Co., Ltd. engages in the research, development, and production of pathological diagnosis products in China. It offers pathological diagnostic reagents and ancillary equipment, including liquid-based cytology, such as gynecological series, non-gynecological series, and equipment; fluorescence in situ hybridization products for various applications in breast, bladder, lung, cervical, prostate, and thyroid cancer; and neuroblastoma, soft tissue sarcoma, other solid tumors, prenatal screening and abortion, oligodendrocytes tumor, lymphoma, multiple myeloma, chronic myelogenous and lymphocytic leukemia, myelodysplastic syndromes, acute myeloid leukemia, and acute lymphoblastic leukemia. The company also provides immunohistochemistry products, which comprise antibodies, detection systems, repair systems, complementary products, and immunohistochemistry kit, as well as molecular genetic diagnosis products. Guangzhou LBP Medicine Science & Technology Co., Ltd. was founded in 2005 and is based in Guangzhou, China.
Past 5 years
USD 3.27
USD 3.72
USD 1.31
USD 1.70
USD 2.79
StockViz Staff
January 15, 2025
Any question? Send us an email